Twitter | Search | |
CardioTomLuscher
Cardiologist. Author. Innovator. My topic: Frontiers in Cardiovascular Disease
195
Tweets
140
Following
2,280
Followers
Tweets
CardioTomLuscher Oct 17
Endocarditis is the Cinderella of cardiology: Still a huge clinical problem, but under-investigated. We try to change this with the current EHJ issue on endocarditis. Get ready for the current evidence with our EHJ Focus Issue:
Reply Retweet Like
CardioTomLuscher Oct 17
Learn more about blood cultures in endocarditis in this Editor’s choice article now out in EHJ:
Reply Retweet Like
CardioTomLuscher Oct 16
Reply Retweet Like
CardioTomLuscher Oct 15
LONDON Shock 2019 continued: Net working of centers with referring hospitals to provide a chain of survival. Bernhard Schiefer showed the impressive German experience: Telemedicine, digitalization chest pain unit networks
Reply Retweet Like
CardioTomLuscher Oct 15
Listen to this interesting podcast 🎧of the European Heart Journal Editorial which is linked to the following article in our journal:
Reply Retweet Like
CardioTomLuscher Oct 15
LONDON Shock 2019: Holger Thiele massage is - if you do not know what works, randomize! Use scores to adapt for risk, PCI only to the culprit artery. ECMO or not, Impella or not: Running trials will give the answer
Reply Retweet Like
CardioTomLuscher Oct 15
LONDON Shock 2019: Addressing the frontier of cardiac care - what works in Cardiogenic Shock? What measures do we have to test? Top researchers discuss the future
Reply Retweet Like
CardioTomLuscher Oct 13
Don’t forget the patient - we sometimes forget that the patient must be in the center: What does he expect: QoLor a longer life, better labs or less symptoms. At the London PCHF we showed the backside of the coin: The experience of a nurse and that of a patient- important!
Reply Retweet Like
CardioTomLuscher Oct 13
CRT-D or CRT-P - that is here the question. At the London Postgraduate Course on Heart Failure Rakesh Sharma, Cecilia Linde and Lars Kober discussed the pros and cons: We need better prediction models to serve those at risk: Personalized Medicine is an unmet need to be addressed.
Reply Retweet Like
CardioTomLuscher Oct 12
Is atrial fibrillation evidence-based: A memorable controversy with Milton Packer /against) and Dipen Shah (pro): We think it improves symptoms and outcome, but do we really know? The evidence-base is small and not at the level of CV medicine - we need larger, better trials
Reply Retweet Like
CardioTomLuscher Oct 12
Pumpers & Splitters: Are we ready to reconsider HFpef, HFmrEF and HFrEF to move forward to presonalized medicine? Read what we discussed at the London Postgraduate Course on Heart Failure in London - its online in the EHJ (T.F. Lüscher: Lumpers and Splitters 2019)
Reply Retweet Like
CardioTomLuscher Oct 12
The London Postgraduate Course on Heart Failure: Exiting speakers such as Milton Packer, Piotr Ponikowski and a great audience discussing the frontiers of pharmacotherapy
Reply Retweet Like
CardioTomLuscher Oct 9
TAVI is on the move: it’s getting more and more a first choice even in younger and healthier patients. Read about current results and complications and how to handle them in the most recent EHJ issue:
Reply Retweet Like
CardioTomLuscher Oct 4
Channelopathies and Sudden death in the young: Read about new insights into genetics and how drugs may act as unintended triggers of their fatal consequences. Have a look at the newest EHJ issue:
Reply Retweet Like
CardioTomLuscher Sep 26
Uninterrupted NOAC is non-inferior to vitamin K antagonist peri-interventional. But a non-significant trend to more events with NOAC; is uninterrupted edoxaban therapy still an alternative to uninterrupted vitamin K antagonist treatment during ablation?
Reply Retweet Like
CardioTomLuscher Sep 24
Now in the European Heart Journal: This analysis from the CONFIRM registry
Reply Retweet Like
CardioTomLuscher retweeted
European Society of Cardiology Sep 16
🎧 & Alexandre Lyon discuss: Development & validation of a multivariable prediction model for major adverse CV events after early stage breast cancer. Listen now here or on your favourite app.
Reply Retweet Like
CardioTomLuscher Sep 19
News on cardioversion and AFib ablation: The ELIMINATE-AF trial shows non-inferiority of edoxaban vs. vitamin K antagonist with trend to more events. And is cardioversion a risk or marker for thromboembolic events? Read the current EHJ issue:
Reply Retweet Like
CardioTomLuscher retweeted
European Society of Cardiology Sep 18
Did you know that the British Medical Association awarded the first prize in cardiology for the ESC Textbook of Cardiovascular Medicine 3rd Edition?
Reply Retweet Like
CardioTomLuscher retweeted
R Brompton Harefield Sep 18
We loved welcoming the public into Harefield's theatres and catheter labs yesterday for our Open Day - fantastic day sharing our work with you all.
Reply Retweet Like